TAP settles charges of inflating Lupron price

Share this article:
TAP Pharmaceuticals reached a settlement with the Wisconsin Department of Justice (WDOJ) to pay $798,000 for fraudulent marketing practices, including the improper influencing of doctors to prescribe high-priced cancer drug, Lupron.
The money will be distributed by court order to 48 Wisconsin organizations engaged in the care and treatment of cancer or the promotion of improved health care for Wisconsin citizens. 
The US Attorney General's Office previously recovered an additional $1.4 million from TAP on behalf of Wisconsin's Medicaid Program.  Both settlements arise out of illegal and improper marketing and sales practices on the part of TAP to induce doctors to prescribe Lupron.
An investigation into TAP's marketing practices revealed that TAP inflated the "Average Wholesale Price" (AWP) for Lupron, the WDOJ said. In order to induce doctors to prescribe Lupron, TAP also deliberately and falsely overstated the average wholesale price of Lupron and provided free samples of Lupron to doctors with instructions to them regarding how to falsely bill Medicaid, Medicare and other third-party payers for the free samples, investigators said. TAP also sent doctors on lavish trips and junkets and paid them under-the-table discounts, rebates and bribes disguised as "educational grants" that the doctors could use for anything they wanted, investigators said.  As a result of these activities, TAP and a number of corporate executives were indicted on criminal charges.  TAP ultimately pleaded guilty and paid over $875 million in criminal fines, restitution and civil penalties.
Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.